Effects of a novel immune modulation therapy in patients with advanced chronic heart failure Results of a randomized, controlled, phase II trial by Torre-Amione, Guillermo et al.
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OBJECTIVE We sought to determine whether a novel, non-pharmacological form of immune modulation
therapy (IMT), shown experimentally to reduce inflammatory and increase anti-inflammatory
cytokines, improved outcomes in patients with advanced heart failure (HF).
BACKGROUND Immune activation contributes to the progression of HF, but treatments directed against
inflammation have been largely unsuccessful.
METHODS Seventy-five HF patients (New York Heart Association [NYHA] functional class III to IV)
were randomized to receive either IMT (n  38) or placebo (n  37) in a double-blind trial
for six months, with continuation of standard HF therapy. Patients were evaluated using the
6-min walk test, changes in NYHA functional class, cardiac function, and quality of life
assessments, as well as occurrence of death and hospitalization.
RESULTS There was no between-group difference in 6-min walk test, but 15 IMT patients (compared
with 9 placebo) improved NYHA functional classification by at least one class (p  0.140).
The Kaplan-Meier survival analysis showed that IMT significantly reduced the risk of death
(p  0.022) and hospitalization (p  0.008). Analysis of a clinical composite score
demonstrated a significant between-group difference (p  0.006). There was no difference in
left ventricular ejection fraction, but there was a trend toward improved quality of life (p 
0.110).
CONCLUSIONS These preliminary findings are consistent with the hypothesis that immune activation is
important in the pathogenesis of HF and establish the basis for a phase III trial to define the
benefit of IMT in chronic HF. (J Am Coll Cardiol 2004;44:1181–6) © 2004 by the
American College of Cardiology Foundationm
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Mhere is convincing evidence that inflammation has a role in
eart failure (HF). In experimental models, inflammatory
ytokines promote left ventricular remodeling (1) and con-
ractile dysfunction (2,3), and uncouple myocardial beta-
drenergic receptors (4). Moreover, cardiac-specific overex-
ression of tumor necrosis factor (TNF)-alpha causes
ardiomyopathy and premature death (5). Clinically, anti-
ytokine therapy (specifically anti–TNF-alpha) has shown
isappointing results. These negative outcomes (6,7) are
erhaps not unexpected. Because a number of inflammatory
ytokines (8) are increased in HF, inhibition of TNF-alpha
lone would not overcome functional duplication within the
nflammatory cascade. Moreover, anti–TNF-alpha treat-
ent would not be expected to increase anti-inflammatory
ytokines.
Support for a less specific approach to immune modula-
ion in HF comes from a series of small trials that docu-
ented benefit from steroids (9), intravenous immunoglob-
lin (10), and immunoadsorption (11).
Recently, preclinical studies have shown that autologous
lood exposed ex vivo to oxidative stress and administered
ntramuscularly decreases the production of inflammatory
From the *Methodist DeBakey Heart Center, Baylor College of Medicine,
ouston, Texas; †Hotel-Dieu du CHUM, Montreal, Quebec, Canada; ‡Texas Heart
nstitute, Houston, Texas; and §The Cleveland Clinic Foundation, Cleveland, Ohio.
upport was provided by Vasogen Inc., Mississauga, Ontario, Canada.
Manuscript received January 15, 2004; revised manuscript received June 3, 2004,Vccepted June 14, 2004.ediators (12–14), increases anti-inflammatory cytokines,
nd decreases apoptosis (14). In human trials of peripheral
rterial disease, such immune modulation therapy (IMT)
as shown to be safe and to improve vascular endothelial
unction (15) and claudication distance (16). Accordingly,
n exploratory study was conducted to compare the safety
nd efficacy of IMT in patients with chronic HF.
ETHODS
atient selection. This was a four-center study with pa-
ients primarily drawn from HF clinics. Individuals 18
ears of age with New York Heart Association (NYHA)
unctional class III to IV, chronic HF, left ventricular
jection fraction (LVEF) 40%, and 6-min walk distance
300 m were enrolled. Patients must have been receiving
tandard medical treatment. Doses of cardiac medications
ust have been stable for two weeks (beta-blockers for three
onths) before randomization.
The ethics committees at participating institutions ap-
roved the protocol. All patients gave written informed
onsent.
tudy treatment. The method of treatment has been
reviously described (16). Briefly, venous blood (10 ml) was
ollected into 2 ml of 4% sodium citrate and transferred to
sterile, single-use container (VC7002, Vasogen Inc.,
ississauga, Ontario, Canada) and inserted into theC7001 Blood Treatment Unit (Vasogen Inc.). There the
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Immune Modulation Therapy September 15, 2004:1181–6lood was exposed to controlled levels of oxidative stress
14.5  1.0 g/ml O3 in medical oxygen and ultraviolet
ight at wavelength 253.7 nm) at a temperature of 42.5 
.0°C for 3 min. Approximately 10 ml of treated blood/
itrate mixture was then administered by slow intragluteal
njection, together with 1 ml of 2% lidocaine.
reatment regimen. Patients received active therapy or
lacebo (10 ml of saline) on two consecutive days, followed
y six monthly injections beginning two weeks later. Pa-
ients and clinicians were blinded. There was an unblinded
perator who drew blood, treated the sample, and admin-
stered the treatment injection. This individual was not
nvolved in patient assessments, and unblinded staff had no
ccess to the treatment area.
tudy procedures. Table 1 details the conduct of the study.
fter a screening/wash-out period of 2 to 14 days, there
ere six months of treatment. Visit 10 (end-of-study)
ccurred 30 days after the last treatment. Patient assess-
ents including NYHA functional class, 6-min walk dis-
ance, Minnesota Living with Heart Failure Quality of Life
uestionnaire, echo-Doppler, electrocardiogram, and blood
nd urine samples were obtained at the time points noted.
linded measures of QTc and QT dispersion (QTd) were
erformed in patients with evaluable electrocardiograms.
he QT intervals were measured from three consecutive
eats in leads II and V4, averaged, and corrected for heart
ate using Fridericia’s formula; QTd was determined by
veraging the QT intervals from three consecutive beats in
ach lead and calculating the difference between the shortest
nd longest value.
Abbreviations and Acronyms
HF  heart failure
IMT  immune modulation therapy
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
TNF  tumor necrosis factor
able 1. Study Flow Chart
Phase of Study
Screening
1 2 3
Visit Time in Study (Days) 14 to 2 1 2
istory and examination X
andomization X
reatment X X
linical assessment, including
adverse events and NYHA
functional class
X X X
MWD test and MLHF QoL
questionnaire
X
2-lead ECG/2D echo Doppler X
lood* and urine† samples X
ytokines,‡ BNP, CRP levels X
Electrolytes, blood urea nitrogen, creatinine, total protein, albumin, calcium, phosph
irect bilirubin, LDH (hepatitis B antigen, and pregnancy test at visit 1 only); †Dip
BNP  brain natriuretic peptide; CRP  C-reactive protein; F/U  follow-up; M
ssociation; QoL  quality of life; 6MWD  6-min walk distance.At the end of study, patients were categorized as im-
roved, unchanged, or worsened according to a clinical
omposite score modified from Packer (17). Patients were
mproved if they had not experienced death or hospitaliza-
ion and had improved NYHA functional class. Patients
ere worsened if they had a major event or worsening of
YHA functional class.
tatistical analyses. The primary end points were changes in
-min walk distance and NYHA functional classification.
econdary end points were changes in cardiac function, all-
ause mortality, all-cause hospitalizations, and Minnesota Liv-
ng with Heart Failure Quality of Life questionnaire score.
xploratory analyses included a clinical composite score and
hange in QTc and QTd.
For end points that had two or more post-treatment
easurements, a repeated-measures analysis of variance
ANOVA) was performed. For discrete end points, logistic
odels were used. Patients withdrawn from therapy for any
eason (including death), had the last observation carried
orward. Cumulative survival curves for the risk of all-cause
ortality and all-cause hospitalization were constructed by
he Kaplan-Meier method; differences between the curves
ere tested for significance using the log-rank statistic. The
nalyses of other variables were descriptive.
ESULTS
atients. Seventy-five patients were randomized, 38 to
MT and 37 to placebo (Fig. 1). One patient randomized to
MT received no study treatment and was excluded from all
nalyses. Another patient randomized to IMT had the final
isit postponed; a decision was made before database closure
nd unblinding not to include this patient’s data in efficacy
nalyses. A total of 5 patients (13.9%) in the IMT and 12
32.4%) in the placebo group discontinued treatment pre-
aturely. As shown in Table 2, the groups were well
atched for all major baseline characteristics. Reasons for
tudy discontinuations are provided in Figure 1.
Treatment F/U
4 5 6 7 8 9 10
14 44 74 104 134 164 194
X X X X X X
X X X X X X X
X X
X
X X
X X
glucose, AST (SGOT), ALT (SGPT), ALP (alkaline phosphatase), total bilirubin,
‡Interleukin-2, interleukin-10, tumor necrosis factor-alpha, and interferon-gamma.
 Minnesota Living with Heart Failure questionnaire; NYHA  New York Heartorus,
stick,
LHF
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September 15, 2004:1181–6 Immune Modulation Therapyrimary and secondary efficacy parameters. Mean 6-min
alk distance for the IMT group was 218  71 m at
aseline and increased 18% at visit 10. For the placebo
roup, mean 6-min walk distance at baseline was 237 
6 m and increased 21% at visit 10 (p  NS). By study end,
5 (41.7%) IMT-treated patients improved their NYHA
unctional class, whereas 3 (8.3%) worsened, compared with
(24.3%) improved and 3 (8.1%) worsened in the placebo
roup. The percentage of patients with improved status
avored the IMT group at visit 10 (p  0.140).
Kaplan-Meier survival analyses showed that IMT signif-
igure 1. Randomization and flow of patient evaluations. IMT immune
odulation therapy; LVAD  left ventricular assist device.
able 2. Demographics and Other Baseline Characteristics:
afety Population
Placebo
n  37
IMT
n  37
ge, yrs 60.3 11.1 63.0 13.4
ale, n (%) 25 (67.6) 26 (70.3)
hite, n (%) 25 (67.6) 26 (70.3)
YHA functional class III/IV, n (%) 36/1 (97.3/2.7) 37/0 (100/0)
VEF, % 21.5 7.5 22.8 7.8
revious myocardial infarction 20 (54.1) 16 (43.2)
revious coronary revascularization 13 (35.1) 13 (35.1)
iabetes 9 (24.3) 16 (43.2)
ystolic blood pressure 111.2 14.9 116.5 19.5
iastolic blood pressure 71.7 9.9 71.5 8.7
eart rate 73.0 12.9 73.7 11.5
NP (pg/ml) 345.7 387.1 432.5 414.6
edication use, n (%)
ACE inhibitor 28 (75.7) 28 (75.7)
Angiotensin-II receptor blocker 5 (13.5) 5 (13.5)
Digitalis 31 (83.8) 30 (81.1)
Beta-blocker 18 (48.6) 20 (54.1)
Diuretics 36 (97.3) 35 (94.6)
Spironolactone 19 (51.4) 15 (40.5)
ata are expressed as mean  SD or n (%).
ACE  angiotensin-converting enzyme; BNP  brain natriuretic peptide; IMT
immune modulation therapy; LVEF  left ventricular ejection fraction; NYHA dew York Heart Association.cantly reduced the risk of death (p  0.022) and of
ospitalization (p  0.008) (Figs. 2 and 3). Patients with at
east one hospitalization (33.3% vs. 56.8%; p  0.061,
isher exact test) and total number of hospitalizations/
atient (0.7 vs. 1.1; p 0.060, Wilcoxon test) favored IMT.
even of 12 first hospitalizations in IMT-treated patients
ere for cardiovascular indication compared with 17 of 21
n the placebo group. There were no between-group differ-
nces in LVEF or circulating levels of interferon-gamma,
NF-alpha, interleukin-6, interleukin-10, brain natriuretic
eptide, and C-reactive protein (Table 3). Change in the
innesota Living with Heart Failure Quality of Life
uestionnaire from baseline trended in favor of IMT (12.2
s. 4.5 point improvement, last observation carried forward,
 0.110).
Although deaths in this trial were not adjudicated, review
f clinical records revealed that four of seven placebo deaths
ere probably arrhythmic. Two were rather typical sudden
and unexpected) out-of-hospital deaths. The remaining
wo patients had worsening HF; one died at home, whereas
he other developed ventricular fibrillation in the postoper-
tive period after cardiac surgery.
The remaining three placebo patients all died in-hospital
n the postoperative period; one developed pseudomonas
epticemia and cardiorenal failure after valve repair and
oronary artery bypass grafting; one developed multiorgan
ailure after heart transplant for worsening HF, and one had
igure 3. Kaplan-Meier estimates of the probability of hospitalization-free
urvival in immune modulation therapy versus placebo groups. The
igure 2. Kaplan-Meier estimates of the probability of survival in the
mmune modulation therapy and placebo groups. The difference was
ignificant (p  0.022; log-rank test).ifference was significant (p  0.008; log-rank test).
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Immune Modulation Therapy September 15, 2004:1181–6ardiorenal failure after open reduction and internal fixation
f a fractured femoral neck.
The one patient who died in the IMT group succumbed
o intestinal bleeding secondary to cholangio carcinoma.
Three of this group died out of hospital; in two, death
as sudden and unexpected, whereas the other had experi-
nced progressive HF. The remaining patient experienced
ardiac arrest in the postoperative period after cardiac
urgery.
xploratory analyses. Mean QTc decreased in IMT pa-
ients (18 ms; n  20) compared with an increase in
lacebo patients (12 ms; n 15), resulting in a significant
etween-group difference at study-end (429  45 ms vs.
63  45 ms, ANOVA, p  0.035). Similar changes
ccurred in QTd; end-of-study values were 59.71  22.85
s vs. 82.08  32.35 ms (p  0.035).
Clinical composite scores (Fig. 4), showed a significant
inear trend in the between-group differences favoring IMT
p  0.006). Compared with placebo, a greater percentage
f IMT patients had improved scores (p  0.046; Fisher
igure 4. Changes in a clinical composite score from baseline to follow-up
isit after six months of treatment with immune modulation therapy (solid
Table 3. Circulating Cytokine and CRP Value
n IM
TNF-alpha (pg/ml)
Baseline 38 31.16 
Change to F/U 32 0.50 
IL-6 (pg/ml)
Baseline 38 9.28 
Change to F/U 32 2.45 
IFN-gamma (IU/ml)
Baseline 38 0.17 
Change to F/U 32 0.00 
IL-10 (pg/ml)
Baseline 38 3.46 
Change to F/U 32 0.48 
CRP (mg/dl)
Baseline 36 4.48 
Change to F/U 31 1.30 
*Analysis of variance. Data are expressed as mean  SD.
CRP  C-reactive protein; F/U  follow-up; IFN  in
TNF  tumor necrosis factor.fars) or placebo (open bars).xact test). Similarly, a lower percent of IMT patients had
orsened scores (p  0.010).
afety. No safety concerns were apparent (Table 4). Al-
ost all patients experienced at least one adverse event. A
otal of 19 adverse events were judged related to study
reatment in the IMT group, compared with 13 in placebo.
nly injection-site-related adverse events occurred at a
elevantly higher rate in IMT (seven patients) versus pla-
ebo (four patients) patients. However, only 12 (4.1%) of
he IMT versus 5 (2.0%) of the placebo injections were
ssociated with an injection-site-related adverse event. A
otal of 14 (37.8%) IMT-treated patients experienced 39
erious adverse events, including 1 death, compared with 67
erious adverse events, including 7 deaths, in 24 placebo
atients. No serious adverse events were considered
reatment-related.
ISCUSSION
his trial was designed to provide preliminary evidence of
afety and efficacy of IMT in chronic HF. Patients had
elatively severe HF as depicted by NYHA functional class,
VEF, and exercise capacity. The mortality rate (18.9% at
.5 months) is higher than observed in some recent HF
rials, but is not inconsistent with others (18–20). Although
hese latter trials had more NYHA functional class IV
atients, the LVEFs were similar to the present study; also,
higher percentage of patients enrolled in our trial received
pironolactone before randomization, which might have
mproved functional class.
Neither of the primary efficacy parameters demonstrated
ignificant between-group differences. However, the analy-
is of these end points was purposefully conservative by
mputing missing data as last observation carried forward.
ecause of the difference in mortality rates, this approach
n Placebo p Value*
36 33.52  15.96
24 2.25  10.32 0.53
36 18.45  32.58
24 0.98  15.98 0.68
36 0.12  0.12
24 0.01  0.09 0.77
36 3.69  7.01
23 1.08  10.24 0.51
36 4.88  3.72
24 0.81  4.29 0.67
n; IL  interleukin; IMT  immune modulation therapy;s
T
12.64
10.24
8.19
10.76
0.44
0.14
7.59
6.99
4.33
4.13
terferoavored the placebo group. Nevertheless, more IMT pa-
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September 15, 2004:1181–6 Immune Modulation Therapyients improved their NYHA functional classification than
he placebo group (p  0.14).
There was a significant reduction in the risk of death and
ospitalization for IMT-treated patients. In addition, the
linical composite score showed a statistical advantage favoring
MT, and there was a trend to improved Minnesota Living
ith Heart Failure Quality of Life questionnaire.
While the precise mechanism of improved outcomes in
MT-treated patients requires further investigation, the
nown biological activity of IMT provides a plausible
xplanation. Current evidence suggests that ex vivo exposure
f blood to oxidative stress produces accelerated “senes-
ence” of immune cells such that they undergo apoptosis
fter intramuscular injection. Interaction of apoptotic cells
ith immune system macrophages results in decreases in
nflammatory and upregulation of anti-inflammatory cyto-
ine production (21). Such modulation of tissue immune
esponses may favorably influence a number of pathologic
rocesses in HF, including myocardial cell death, left ventric-
lar dysfunction, and electrophysiologic abnormalities.
There were no changes in circulating cytokine levels.
owever, cytokines are local effectors, and changes in tissue
evels are not necessarily reflected in changes in plasma
oncentrations (22). Moreover, only 55 patients had both
aseline and end-of-study measurements. Other than the
mall sample size, we have no explanation for the lack of
mpact on brain natriuretic peptide, C-reactive protein, or
VEF. All these issues require assessment in a larger study.
Because four of seven placebo patients most likely suf-
ered arrhythmic deaths, an analysis of QTc and QTd was
ndertaken to assess arrhythmic substrate in survivors.
aseline QTc was prolonged, and QTc and QTd both
ncreased in the placebo-treated patients but decreased in
hose receiving IMT, suggesting a reversal of electrophysi-
logic remodeling (23). More interestingly, because QTc
able 4. Frequency of AEs
Placebo
n  37
IMT
n  37
atients with 1 AE (%) 37 (100) 34 (91.9)
atients with 1 injection site AE (%) 4 (10.8) 7 (18.9)
otal adverse events in study n  290 n  275
ardiovascular
Arrhythmia 8 (2.8) 12 (4.4)
Angina pectoris 10 (3.4) 8 (2.9)
Hypotension 4 (1.4) 5 (1.8)
Syncope 3 (1.0) 3 (1.1)
enal failure 1 (0.3) 2 (0.7)
njection site
Edema 0 1 (0.4)
Ecchymosis 1 (0.3) 2 (0.7)
Pain 3 (1.0) 9 (3.3)
Paresthesia 1 (0.3) 0
nfection-related
General 7 (2.4) 8 (2.9)
Respiratory 25 (8.6) 20 (7.3)
ata are expressed as number (%).
AE  adverse event; IMT  immune modulation therapy.uration may also be a marker of the severity of HF, theeduction in QTc duration observed in the IMT-treated
atients may provide another signal of the biological effect
f IMT (24). Interpretation of these data should be cau-
ious, however, because analysis was retrospective and con-
ucted in the subset of evaluable patients.
tudy limitations. The major limitation of this study is
mall sample size. This increases the possibility that the
igh mortality rate in the placebo group and, therefore, the
bserved benefit from IMT occurred by chance alone.
owever, it is important to note that, in addition to the
educed mortality in the IMT group, there were also fewer
otal and cardiovascular hospitalizations, improved compos-
te clinical scores, decreased QTc and QTd in survivors, and
trend toward improved quality of life.
onclusions. Although a preliminary study that must be
nterpreted with caution, the findings are consistent with
he hypothesis that immune-activation plays an important
ole in the pathogenesis of HF. Given the lack of detrimen-
al hemodynamic and other adverse effects, IMT could be
afely combined with standard HF therapies. The observa-
ions from this study have established the basis for a phase
II clinical trial to define the full benefit of this novel
herapy in chronic HF.
eprint requests and correspondence: Dr. Guillermo Torre-
mione, Methodist DeBakey Heart Center and Baylor College of
edicine, 6550 Fannin, Suite 1901, Houston, Texas 77030.
-mail: gtorre@bcm.tmc.edu.
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